— Know what they know.
Not Investment Advice

SMMT NASDAQ

Summit Therapeutics Inc.
1W: +7.4% 1M: +14.8% 3M: +5.2% YTD: -4.3% 1Y: -18.2% 3Y: +772.9% 5Y: +221.1%
$16.75
+0.07 (+0.39%)
 
Weekly Expected Move ±7.4%
$14 $16 $17 $18 $19
NASDAQ · Healthcare · Biotechnology · Tech Score Neutral · Power 60 · $13.4B mcap · 110M float · 5.41% daily turnover · Short 56% of daily vol

Cash Flow Trends

Operating Cash Flow
-$323M -127.2% ▼
Capital Expenditures
$657K -372.7% ▼
5Y CAGR: +9.3%
Free Cash Flow
-$324M -127.5% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
$120M +256.6% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$89M-$79M-$615M-$221M-$1.1B
Depreciation & Amort.$2M$3M$2M$89K-$7M
Stock-Based Comp.$9M$10M$14M$51M$732M
Change in Working Capital-$67K$9M-$2M$15M$23M
Other Non-Cash Items$497K$14M$524M$13M$8M
Operating Cash Flow-$73M-$42M-$77M-$142M-$323M
— Investing Activities —
Capital Expenditures-$306K-$624K-$128K-$139K-$657K
Acquisitions (Net)$0$0$0$0$0
Investment Purchases$0$0-$321M-$680M-$485M
Investment Sales$0$0$208M$490M$311M
Other Investing$0-$600-$475M-$15M$0
Investing Cash Flow-$306K-$624K-$588M-$205M-$174M
— Financing Activities —
Net Debt Issuance$0$520M-$25M-$100M$0
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$3M$100M$106M$3M$159M
Financing Cash Flow$78M$620M$87M$381M$618M
Net Change in Cash$5M$577M-$577M$34M$120M
Cash End of Period$72M$649M$71M$105M$226M
Free Cash Flow-$73M-$42M-$77M-$142M-$324M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms